Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Sarah M. Larson, MD

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Sarah M. Larson, MD
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 21 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- Sign up for this study
- ID
- NCT05317416
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 760 study participants
- Last Updated